With coronavirus lockdowns easing but few new movies to show, some cinemas plan to reopen with classics including 'Jaws,' 'Back to the Future' and 'Psycho'
For such older titles, studios are planning to take as little as 30% of ticket revenue, according to people familiar with the matter, a discount from the typical 50-50 split on new films, which have production and marketing budgets that studios need to recoup.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
WSJ News Exclusive | Some Americans Are Being Turned Away Trying to Buy Life InsuranceThe driving force behind the action: a collapse in interest rates tied to the spread of the new coronavirus and an expectation from insurers that rates won’t rebound significantly anytime soon.
Lire la suite »
WSJ News Exclusive | A Mediterranean-Style Home on Malibu’s Broad Beach Lists for $42 MillionThe 13,500-square-foot estate is one of the largest in the area, which is a favorite among celebrities.
Lire la suite »
WSJ News Exclusive | Endeavor Group Secures $260 Million Loan to Help Business Battered by CoronavirusEndeavor Group Holdings has secured a $260 million term loan to help shore up the entertainment company’s business, which has been hammered by the coronavirus pandemic, according to people familiar with the matter.
Lire la suite »
WSJ News Exclusive | U.S. Government Drafts Guidelines for Reopening Hard-Hit Nursing HomesFederal health regulators are developing guidelines for reopening nursing homes, people with knowledge of the matter say, proposing steps to allow visitors to return to facilities that have been hit hard by the coronavirus despite lockdowns.
Lire la suite »
WSJ News Exclusive | Remdesivir Distribution ‘Misalignment’ Shouldn’t Happen Again, Coronavirus Leader SaysDr. Deborah Birx, in a May 7 email sent to fellow Trump administration task force members and other senior officials, said her colleagues would review how the decision-making led to a “misalignment” of the drug’s allocation.
Lire la suite »